Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

This study is testing a combination of two targeted cancer drugs — dabrafenib and trametinib — in people with rare solid tumours that carry a specific genetic change called the BRAF V600E mutation. This mutation acts like a stuck accelerator in cancer cells, and these drugs are designed to switch it off. **You may be eligible if...** - You have a solid tumour confirmed to carry the BRAF V600E mutation (by a lab test) - You have at least one measurable tumour - You have not previously been treated with dabrafenib or trametinib (or stopped treatment more than 1 year ago) **You may NOT be eligible if...** - Your tumour does not carry the BRAF V600E mutation - You have previously received and recently discontinued dabrafenib or trametinib - You have certain serious medical conditions affecting your heart, liver, or eyes Talk to your doctor to see if this trial is right for you.